Medical/Pharmaceuticals
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...
2025-02-18 17:00
2751
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
* 'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. * Preclinical studies in multiple animal models confirm significant improvements in key disease indi...
2025-02-18 15:00
2422
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent to U.S. and European reference Apixaban tablets (Eliquis®) ...
2025-02-17 21:03
2868
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as...
2025-02-17 19:25
2121
Singapore launches Mental Health Innovation Asia Hub at international symposium
* High demand: Mental health now tops health concerns in Singapore, surpassing cancer and COVID-19. * New regional hub: MHIN Asia Hub, based in Singapore, aims to share innovative resources and ideas to promote mental health support across Asia. SINGAPORE, Feb. 17, 2025 /PRNewswire/ -- In a s...
2025-02-17 18:20
3932
Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
SHANGHAI, Feb. 17, 2025 /PRNewswire/ -- Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transforma...
2025-02-17 16:22
3024
Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide
RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time, Grindeks products will be delivered toPanama. The company's export markets already in...
2025-02-17 15:00
2641
Stryker launches ProCeed hospital bed
New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S. PORTAGE, Mich., Feb. 17, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of the ProCeed hospital bed, offering simplicity while enhancing care a...
2025-02-17 08:07
2292
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-02-17 08:00
3185
Navi Medical Technologies' Neonav® ECG Tip Location System Receives FDA 510(k) Clearance
Revolutionising Vascular Access Care for Critically Ill Newborns and Children Key Points: * FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access care. * First-of-its-kind Innovation: Neonav® is the onl...
2025-02-17 03:00
2737
ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held inSan Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the lates...
2025-02-15 11:02
4265
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that theHong Kong ...
2025-02-14 22:30
4466
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed Series A financing of approximately $90 million....
2025-02-14 21:56
3462
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by the Company's wholly-owned subsidiary, Shenzhen K...
2025-02-14 21:00
3441
Duke and Duke-NUS forge new frontiers in climate health research with S$1million funding
* The two institutions awarded more than S$1 million to accelerate five promising areas of research collaboration * Dedicated Research Collaboration Pilot Project grant combines expertise from Singapore and the US for bigger impact * First time in the grant's 15-year history that it focuses e...
2025-02-14 15:18
3616
Harbour BioMed Announces Business Progress and Update
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, ...
2025-02-14 12:08
3821
Axel Klarmeyer Joins Chamlion as CEO, Chamlion International
NANJING, China, Feb. 14, 2025 /PRNewswire/ -- Chamlion, a pioneer in integrated dental 3D printing solutions, is pleased to announce the appointment ofAxel Klarmeyer as the CEO of Chamlion International, overseeing the company's international business operations. Axel's extensive industry experie...
2025-02-14 10:34
2451
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2...
2025-02-14 09:11
2077
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
* Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson * Introducing 'Countmate': A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Techn...
2025-02-14 08:35
2486
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patien...
2025-02-13 18:53
1746
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
True 1000Hz Powerhouse: PHILIPS EVNIA Unleashes the World's First 1000Hz Dual-Mode Gaming Monitor 27M2N5500XD
[Picked up by 282 media titles]
2026-01-29 18:03
